Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease

Abstract excerpt

Chronic graft-versus-host disease (GVHD) occurs in 30-70% of patients after allogeneic hematopoietic cell transplantation (HCT) and increases the risks of morbidity and mortality. Systemic corticosteroids are the standard initial treatment, but one-third of patients require subsequent treatment with other systemic agents. Treatment decisions are often based on physicians' experience. The expected treatment...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hematopoietic Stem Cell Transplantation
• Share to Mesenchymal stem cell research
• Share to Pancreatic function and diabetes